Restoring Vision Through Regenerative Medicine
March 11, 2026
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
February 17, 2026
GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership
March 3, 2022
HTL Announces Its Incubator's Equity Investment In GelMEDIX, An Early-Stage Biotech Aiming At Revolutionizing Ocular And Regenerative Therapies
June 29, 2021
GelMEDIX Wins Golden Ticket at LabCentral from AbbVie
